Monopar Therapeutics Stock Year To Date Return

MNPR Stock

USD 25.82 2.03 8.53%

Monopar Therapeutics fundamentals help investors to digest information that contributes to Monopar Therapeutics' financial success or failures. It also enables traders to predict the movement of Monopar Stock. The fundamental analysis module provides a way to measure Monopar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Monopar Therapeutics stock.

Total Current Liabilities Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Monopar Therapeutics Company Year To Date Return Analysis

Monopar Therapeutics' Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.

YTD Return

(Mean of Monthly Returns - 1)

X

100%

More About Year To Date Return | All Equity Analysis

Monopar Year To Date Return Driver Correlations

Understanding the fundamental principles of building solid financial models for Monopar Therapeutics is extremely important. It helps to project a fair market value of Monopar Stock properly, considering its historical fundamentals such as Year To Date Return. Since Monopar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Monopar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Monopar Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Common Stock	Capital Stock	Short Term Debt
Total Assets		0.99	0.82	-0.72	0.69	0.68	1.0	-0.97	0.86	0.61	0.69	0.61	0.61	-0.14
Total Stockholder Equity	0.99		0.76	-0.66	0.59	0.59	0.99	-0.98	0.81	0.65	0.72	0.54	0.53	-0.11
Net Tangible Assets	0.82	0.76		-0.91	0.88	0.88	0.83	-0.78	0.98	0.27	0.36	0.9	0.89	-0.3
Retained Earnings	-0.72	-0.66	-0.91		-0.86	-0.86	-0.74	0.62	-0.91	0.03	-0.07	-0.94	-0.94	0.63
Accounts Payable	0.69	0.59	0.88	-0.86		1.0	0.7	-0.55	0.83	0.16	0.24	0.86	0.85	-0.27
Total Liab	0.68	0.59	0.88	-0.86	1.0		0.7	-0.55	0.83	0.16	0.24	0.85	0.85	-0.27
Total Current Assets	1.0	0.99	0.83	-0.74	0.7	0.7		-0.97	0.87	0.6	0.67	0.63	0.63	-0.15
Net Debt	-0.97	-0.98	-0.78	0.62	-0.55	-0.55	-0.97		-0.82	-0.69	-0.76	-0.54	-0.53	0.04
Capital Surpluse	0.86	0.81	0.98	-0.91	0.83	0.83	0.87	-0.82		0.25	0.35	0.84	0.83	-0.31
Net Invested Capital	0.61	0.65	0.27	0.03	0.16	0.16	0.6	-0.69	0.25		0.99	0.02	0.0	0.52
Net Working Capital	0.69	0.72	0.36	-0.07	0.24	0.24	0.67	-0.76	0.35	0.99		0.11	0.09	0.46
Common Stock	0.61	0.54	0.9	-0.94	0.86	0.85	0.63	-0.54	0.84	0.02	0.11		1.0	-0.59
Capital Stock	0.61	0.53	0.89	-0.94	0.85	0.85	0.63	-0.53	0.83	0.0	0.09	1.0		-0.63
Short Term Debt	-0.14	-0.11	-0.3	0.63	-0.27	-0.27	-0.15	0.04	-0.31	0.52	0.46	-0.59	-0.63

Click cells to compare fundamentals

Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.

Competition

Predict Monopar Therapeutics

Monopar Return On Tangible Assets

Return On Tangible Assets

(1.2)

At this time, Monopar Therapeutics' Return On Tangible Assets are relatively stable compared to the past year.

Based on the company's disclosures, Monopar Therapeutics has a Year To Date Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Monopar Year To Date Return Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monopar Therapeutics' direct or indirect competition against its Year To Date Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics of similar companies.

Monopar Therapeutics is currently under evaluation in year to date return category among its peers.

Monopar Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Monopar Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Monopar Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Monopar Fundamentals

	Return On Equity	-1.02
	Return On Asset	-0.53
	Current Valuation	127.95 M
	Shares Outstanding	5.28 M
	Shares Owned By Insiders	42.94 %
	Shares Owned By Institutions	24.47 %
	Number Of Shares Shorted	21.98 K
	Price To Earning	(35.82) X
	Price To Book	27.33 X
	EBITDA	429.04 K
	Net Income	(8.4 M)
	Cash And Equivalents	16.46 M
	Cash Per Share	1.29 X
	Total Debt	1.76 M
	Debt To Equity	0 %
	Current Ratio	7.61 X
	Book Value Per Share	1.88 X
	Cash Flow From Operations	(7.86 M)
	Short Ratio	0.15 X
	Earnings Per Share	(2.13) X
	Target Price	27.33
	Beta	1.1
	Market Capitalization	136.27 M
	Total Asset	7.35 M
	Retained Earnings	(60.21 M)
	Working Capital	5.58 M
	Current Asset	11.55 M
	Current Liabilities	598.26 K
	Net Asset	7.35 M

About Monopar Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Monopar Stock

0.61

DMAC

DiaMedica Therapeutics Upward Rally

Pair Corr

Moving against Monopar Stock

0.85	DTIL	Precision BioSciences	Pair Corr
0.83	ME	23Andme Holding	Pair Corr
0.8	VALN	Valneva SE ADR	Pair Corr
0.8	DOMH	Dominari Holdings	Pair Corr
0.78	VINC	Vincerx Pharma	Pair Corr

The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.

The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC